Evaluation of Human Hepatocyte Drug Metabolism Carrying High-Risk or Protection-Associated Liver Disease Genetic Variants

Abstract excerpt

Metabolic-dysfunction-associated steatotic liver disease (MASLD), which affects 30 million people in the US and is anticipated to reach over 100 million by 2030, places a significant financial strain on the healthcare system. There is presently no FDA-approved treatment for MASLD despite its public health significance and financial burden. Understanding the connection between point mutations, liver enzymes, and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Transport and Resistance Mechanisms
• Share to Liver Disease Diagnosis and Treatment
• Share to Pharmacogenetics and Drug Metabolism